INTRODUCTION

Cardiovascular diseases, the major cause of morbidity and mortality worldwide, consist of a group of disorders of the heart and blood vessels [1]. Accumulating evidence suggests that the inflammation of vascular smooth muscle cells (VSMC) is a basic pathological feature of vascular dysfunction associated with vascular diseases [2, 3]. Recent insights into the pathogenesis of inflammatory vascular diseases underscore the importance of induced expression of proinflammatory adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1), which occurs in VSMC [2]. Plasma trimethylamine N-oxide (TMAO), a metabolite of the dietary lipid phosphatidylcholine, has been proven to be associated with an increased risk of major cardiovascular diseases in both human and animal-model studies [4, 5]. TMAO has been demonstrated to activate protein kinase-like ER kinase and enhance reactive oxygen species (ROS) generation in VSMC, which augmented angiotensin II-induced vasoconstriction [6]. However, a clear mechanistic link between TMAO and vascular inflammation is not yet established. Identifying the mechanisms underlying TMAO-induced VSMC inflammation is a crucial step toward the development of effective therapeutics.

Epigenetic modulators have been shown to play a major role in the regulation of vascular, immune, and tissue-specific gene expressions within atherosclerotic lesions [7]. Protein arginine methyltransferase 5 (PRMT5), the primary type II histone methyltransferase, contains a triosephosphate isomerase-barrel fold and possesses histone symmetric demethylase activity [8]. Previous studies have indicated that PRMT5 participates in numerous pathophysiological processes through modulating cell proliferation [9], inflammation [10], and tumor formation [11]. PRMT5 has also been implicated in epigenetic regulation of cell adhesion by transcriptional repression of the E-cadherin gene [12]. Despite recent advances on its role in endothelial inflammation [13], whether PRMT5 is involved in modulating VSMC inflammation remains elusive.

Here, we reported for the first time that aberrant PRMT5 overexpression positively correlated with TMAO-induced vascular inflammation. Mechanically, PRMT5 post-translationally methylated nuclear factor-κB (NF-κB) p65 subunit, a step imperative to the VCAM-1 induced by TMAO. Furthermore, we found that the TMAO-induced PRMT5 expression was mediated at least in part through upregulation of Nox4 and subsequent production of H2O2. Elucidating the role of TMAO and its underlying mechanisms during VSMC inflammation may provide new insights into the prevention and treatment of TMAO-related cardiovascular events.

RESULTS

TMAO induces PRMT5 and VCAM-1 expression in VSMC

To evaluate potential cytotoxic effect of TMAO on primary rat VSMC, the cells were incubated with TMAO (100–2 000 μM) for 24 h or incubated with TMAO (600 μM) for the indicated periods...
and cell viability was evaluated by MTT assay. As shown in Fig. 1A, B, TMAO at the concentration range from 100 to 2000 μM did not affect the cell viability, indicating non-cytotoxic effect of TMAO observed under above condition. Importantly, TMAO (100–1000 μM) treatment dose-dependently induced PRMT5 and VCAM-1 expression in primary cultures of rat and human VSMC (Fig. 1C and Suppl. Fig. 1A). In addition, treatment of both primary rat and human VSMC with TMAO (600 μM) induced PRMT5 and VCAM-1 expression in a time dependent manner (Fig. 1D and Suppl. Fig. 1B). Taken together, these results indicate that upregulation of PRMT5 is correlated with TMAO-induced VCAM-1 expression in VSMC.

**PRMT5 positively regulates TMAO-induced VCAM-1 and inflammatory cytokine expression in VSMC**

Next, the role of PRMT5 on VCAM-1 expression in TMAO-stimulated VSMC was investigated. As shown in Fig. 2A and Suppl. Fig. 2, PRMT5 siRNA, but not scrambled siRNA, dramatically diminished TMAO-induced VCAM-1 expression in both primary rat and human VSMC. As expected, PRMT5 overexpression by transfection with a PRMT5 cDNA plasmid aggravated TMAO-induced VCAM-1 expression (Fig. 2B). Consistent with the results on the expression of VCAM-1, adhesion of BMDM was remarkably increased when VSMC were stimulated with TMAO, which was significantly attenuated by PRMT5 siRNA, but not scrambled siRNA. Conversely, PRMT5 overexpression by plasmid transfection further promoted the adhesion of BMDM to VSMC (Fig. 2C). Furthermore, transfection with PRMT5 siRNA, but not scrambled siRNA, dramatically reduced TMAO-induced mRNA expression of pro-inflammatory cytokines including IL-6 and IL-1β (Suppl. Fig. 3). Taken together, our results demonstrate that PRMT5 is critical for TMAO-induced VCAM-1 and pro-inflammatory cytokine expression in VSMC.

**PRMT5 promotes TMAO-induced VCAM-1 expression via methylation of NF-κB p65**

Activation of NF-κB is crucial for driving VCAM-1 gene expression [14]. To examine whether PRMT5 enhanced TMAO-induced VCAM-1 expression through modulating NF-κB p65 activation, VSMC were pretreated with a specific NF-κB inhibitor BAY 11-7085. As shown in Fig. 3A, BAY 11-7085 mitigated TMAO-stimulated VCAM-1 expression. Co-immunoprecipitation analysis further demonstrated that the interaction between PRMT5 and NF-κB p65 subunit was significantly increased in TMAO-stimulated VSMC (Fig. 3B). To further explore how PRMT5 affected the activation of NF-κB p65, the arginine methylation levels of NF-κB p65 were
analyzed by co-immunoprecipitation with anti-symmetrical dimethylarginine (SYM-10) antibody. As shown in Fig. 3C, TMAO stimulation caused symmetrical dimethylation of NF-κB p65 in a time dependent manner. PRMT5 silencing markedly reduced the level of arginine dimethylation of NF-κB p65, while PRMT5 overexpression further enhanced the level of arginine dimethylation of NF-κB p65 in TMAO-stimulated VSMC (Fig. 3D). In addition, overexpressing NF-κB p65, but not NF-κB p65 R30A mutant, significantly increased the level of arginine dimethylation of NF-κB p65 in TMAO-stimulated VSMC (Fig. 3E). To evaluate the effect of NF-κB p65 R30A mutation on the expression of VCAM-1, endogenous NF-κB p65 was knocked down by siRNA and then transfected with wild-type cDNA or mutant p65 cDNA (R30A). As shown in Fig. 3F, overexpressing wild-type NF-κB p65 cDNA, but not NF-κB p65 R30A mutant, significantly increased the level of VCAM-1 expression in TMAO-stimulated VSMC.

Next, we investigated whether PRMT5 contributed to vascular inflammation in vivo using a classical wire injury-induced vascular inflammation model on carotid arteries. SMC-specific PRMT5 knockout (SMC-PRMT5-KO) mice were applied to verify the role of PRMT5 in vascular inflammation (Suppl. Fig. 4). As shown in Suppl. Figure 5, plasma TMAO levels in both SMC-Cre and SMC-PRMT5-KO mice were raised by exogenous TMAO administration. We observed that TMAO treatment significantly increased the expression of VCAM-1 and the macrophage marker CD68 in injured carotids of SMC-Cre mice (Fig. 4A, B). These changes were obviously reduced in TMAO-exposed SMC-PRMT5-KO mice.

Western blot analysis further confirmed that expression of VCAM-1 and PRMT5 was greatly increased in TMAO-exposed injured SMC-Cre carotids. In contrast, expression of VCAM-1 was much lower in injured carotids of TMAO-exposed SMC-PRMT5-KO mice than in SMC-Cre mice (Fig. 4C). To further verify whether arginine methylation detected on NF-κB p65 is catalyzed by PRMT5 in vivo, we examined the symmetrical dimethylation of NF-κB p65 in injured arteries of TMAO-exposed SMC-PRMT5-KO mice. SMC-specific PRMT5 knockout resulted in a substantial decrease in arginine methylation levels of TMAO-exposed wire injured carotid arteries (Fig. 4D). Together, these results suggest that PRMT5 regulates VCAM-1 expression via dimethylation of NF-κB p65 on R30.

Nox4 is involved in TMAO-induced PRMT5 and subsequent VCAM-1 expression

It has been shown that ROS shape the epigenetic landscape and contribute to VSMC inflammatory responses [15, 16]. Importantly, NADPH oxidase family plays an important role in regulating VCAM-1 expression [17, 18]. To clarify whether NADPH oxidases were involved in TMAO-stimulated PRMT5 and subsequent VCAM-1 expression, the subtypes of NADPH oxidase were analyzed by Western blot. As shown in Fig. 5A, TMAO time-dependently upregulated Nox4 protein expression. In contrast, Nox2 upregulation was delayed, occurring at 8 h post-TMAO stimulation, and its magnitude of upregulation was lower than Nox4 (2.01-fold vs. 2.67-fold for Nox2 upregulation vs. Nox4 upregulation at 8 h).
Unlike Nox4 and Nox2, Nox1 expression was not affected by TMAO. In addition, TMAO-induced ROS generation was also measured by DHE staining and Amplex red assay. However, transfection with Nox4 siRNA, but not Nox2 or scrambled siRNA, significantly attenuated TMAO-induced H2O2 production (Fig. 5B) and O2•− levels (Fig. 5C).

We next examined the role of Nox4 in TMAO-induced VSMC inflammation. Pretreatment with N-acetyl-L-cysteine (a nontargeted ROS scavenger, NAC, 1 mM) resulted in a dramatic decrease of TMAO-induced PRMT5 expression, accompanied with reduction of VCAM-1 expression (Fig. 6A). Meanwhile, treatment of VSMC with H2O2 (50 μM) resulted in enhanced PRMT5 and VCAM-1 expression (Fig. 6A), indicating that H2O2 was involved in TMAO-induced upregulation of PRMT5 expression. Notably, Nox4 silencing abolished TMAO-induced PRMT5 expression in VSMC (Fig. 6B). Furthermore, TMAO-induced VCAM-1 expression...
was markedly reduced by pretreatment with NAC (1 mM) for 2 h (Fig. 6C). In contrast, Nox2 knockdown did not affect the expression of VCAM-1 (Suppl. Fig. 6A). Consistent with the results of Nox4 expression, BMDM adhesion was remarkably increased when VSMC were stimulated with TMAO for 24 h (Fig. 6D), while Nox4 silencing, but not Nox2 knockdown, significantly attenuated BMDM adhesion to TMAO-stimulated VSMC (Suppl. Fig. 6B).

Collectively, these data indicate that the upregulation of Nox4 contributes to TMAO-induced PRMT5 and VCAM-1 expression in VSMC.

TMAO-mediated Nox4-NF-YA signaling activation positively regulates PRMT5

It is reported that nuclear factor-YA (NF-YA) is critical for PRMT5 expression [19]. As shown in Fig. 7A, incubation with TMAO elicited a peak level of NF-YA expression at 4 h, followed by gradual dropping. Consistent with TMAO-induced expression of PRMT5, Nox4 knockdown, or NAC treatment significantly inhibited TMAO-induced NF-YA expression. H2O2 treatment alone markedly induced NF-YA expression (Fig. 7B). More importantly, NF-YA knockdown abolished TMAO-induced PRMT5 expression in VSMC.

Fig. 4 PRMT5 contributes to TMAO induced vascular inflammation in vivo. SMC-PRMT5-KO or SMC-Cre mice were subjected to wire-induced carotid artery injury. TMAO (86 μmol) or saline was administered daily by intraperitoneal injection for 7 days. A Representative photomicrographs for VCAM-1 in carotid arteries at 7 days after wire injury. Scale bar, 50 μm. B Representative photomicrographs for CD68 in carotid arteries at 7 days after wire injury. Scale bar, 50 μm. C Representative blots and quantitative analysis of VCAM-1 and PRMT5. The protein expression level was normalized to β-actin. D Representative blots of arginine methylation of p65. Immunoprecipitated SYM10 was blotted with an antibody against p65. Data shown are means ± SD, n = 6 per group from three independent experiments. ***P < 0.001 using a one-way ANOVA followed by Tukey's post hoc test.
choline/L-carnitine and metabolism by the gut microbiome, has therapeutic strategies for TMAO-induced vascular diseases. Highlight the potential of targeting PRMT5 for developing new (Fig. 7C). Taken together, these results suggested that the Nox4-NF-YA signaling positively regulates PRMT5 expression.

DISCUSSION

Several clinical and metabolic studies have demonstrated an association between increased TMAO level and the development of inflammatory vascular diseases [20, 21]. However, the exact mechanisms remain to be explored. In the present study, we show for the first time that the critical role of PRMT5 in TMAO-induced vascular inflammation. PRMT5 knockdown significantly attenuated TMAO-induced VCAM-1 expression and the adhesion of BMDM to VSMC. Mechanistically, we show that arginine methylation of the NF-κB p65 on R30 homology domain by PRMT5 is critical for TMAO-stimulated induction of VCAM-1 (Fig. 8). Thus, our results highlight the potential of targeting PRMT5 for developing new therapeutic strategies for TMAO-induced vascular diseases.

TMAO, a complex compound derived from phosphatidyl choline/L-carnitine and metabolism by the gut microbiome, has been now recognized as a contributor to inflammatory vascular diseases [22, 23]. In human clinical studies, increased TMAO levels were associated with increased risks of major adverse cardiovas- cular events [24, 25]. Nevertheless, it has been suggested that TMAO exposure can induce the expression of cytokines and adhesion molecules such as VCAM-1 both in vivo and in vitro [26, 27]. Consistent with these findings, our results showed that TMAO positively regulated VCAM-1 expression in VSMC, leading to increased macrophage adhesion, which plays a vital role in foam cell formation. However, the molecular mechanisms underlying TMAO-induced VCAM-1 expression, and subsequent events remain to be further elucidated. In this regard, the present study for the first time found that TMAO upregulated PRMT5 expression, and PRMT5 upregulation contributed to TMAO-associated VSMC inflammation. By knocking down or overexpressing PRMT5 in VSMC, we showed that PRMT5 was required for VCAM-1 expression and the adhesion of BMDM to TMAO-stimulated VSMC. Our findings agree with an earlier report that aberrant PRMT5 expression is associated with the endothelial cell inflammatory response [13].

There is an emerging body of evidence that PRMT5 plays an important role in modulating transcription by catalyzing symmetric dimethylation on histones [28]. For example, Cao et al. reported that PRMT5 regulated IL-12 expression by arginine modification of histone in innate immunity [29]. PRMT5 can also methylate nonhistone proteins, such as the transcription factors p53 [30], HOXA9 [13], and p65 [31]. Although PRMT5 has been linked with essential cellular processes such as gene regulation, cell proliferation, and differentiation, its role has yet to be described in VSMC inflammatory activation. In this study, we provided unique insights regarding how PRMT5 upregulation might promote VSMC inflammation, i.e., via symmetrically dimethylated NF-κB p65 on arginine 30 (R30). Previous studies have demonstrated that NF-κB p65 is involved in inflammatory activation that occurs at sites of atherosclerotic [32, 33]. During inflammation, NF-κB p65 activation is sufficient for the expression of VCAM-1 [34, 35]. Post-translational modifications of NF-κB p65 are recognized as a primary driver for the context-dependent gene transcription, including phosphorylation, acetylation, lysine methylation, and ubiquitination [36-38]. Accordantly, we found that TMAO promoted NF-κB p65 methylation. Recent studies have shown that plant homeodomain finger protein 20 (PHF20) promotes NF-κB p65 transcriptional activity by interacting with NF-κB p65 in a methylation-dependent manner, which leads to persistent NF-κB p65 phosphorylation [39]. Furthermore, accumulating evidence supports the important role of dimethyl R30 in increasing the transcriptional ability of NF-κB p65 [31, 40].
Similarly, we found that p65 was dimethylated on R30 by PRMT5 following TMAO stimulation, leading to activation of NF-κB p65 responsible for the expression of VCAM-1.

The potential mechanisms of TMAO-induced PRMT5 expression were further investigated in this study. Current advances about epigenetics have revealed a parallel scenario showing the influence of oxidative stress as a major regulator of epigenetic gene regulation via modification of DNA methylation, histones, and microRNAs [41]. Oxidative stress induced by excess ROS production has emerged as a critical contributor to the initiation and progression of vascular diseases [42, 43]. Several recent studies have reported the putative roles of different Nox isoforms in VSMC that generate ROS, and the subsequent repercussions on VSMC proliferation and inflammatory cell migration that contribute to vascular disease progression [44–47]. In this study, we found that Nox4-generated H₂O₂ was involved in TMAO-induced...
upregulation of PRMT5. Besides, Nox4 silencing significantly attenuated BMDM adhesion to TMAO-stimulated VSMC. Consistently, a Nox4/RhoA/focal adhesion kinase-dependent VSMC adhesion has also been recently reported [48].

Taken together, we demonstrate that PRMT5 promotes TMAO-induced inflammatory response in VSMC in vitro and in vivo. This occurs through PRMT5-mediated dimethylation of NF-κB p65 on Arg-30. Overall, our data support targeting PRMT5 as a potential therapeutic strategy for the treatment of TMAO-associated VSMC inflammation and the related diseases.

MATERIALS AND METHODS

Animals

All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011) and were approved by the Animal Ethics Committee of Jiangnan University (JN.NO20180615C1440210). SMC-specific PRMT5-KO (SMC-PRMT5-KO) mice were created by crossing PRMT5\textsuperscript{flox/flox} mice (stock No. T008183, GemPharmatech Co. Ltd., Nanjing, China) with SM22\textsuperscript{α}-Cre mice (B6. Cg- Tg [Tagln-cre] 1Her/J; stock No. 017491; Jackson Laboratory). PRMT5\textsuperscript{flox/flox} mice were genotyped using the primers 5′-TTCTCTAGGGCCTTGAAGACTGGG-3′ and 5′-GGGCAATCTTTACACTAAC-3′. Their age-matched and gender-matched littermate SMC-Cre mice on a C57BL/6 background were used as control mice. SMC-PRMT5-KO mice were identified through Western blot analysis.

Wire injury-induced vascular inflammation model

Male mice (24–28 g, 10–12-week-old) underwent complete carotid artery injury. In brief, the mice were anesthetized with isoflurane in oxygen. The
left carotid artery was carefully exposed, and the external carotid artery was ligated with an 8-0 suture immediately proximal to the bifurcation of the internal and external carotid arteries. Wire-induced denudation injury was achieved by removing the endothelium with a guidewire (0.38 mm in diameter, No. C-SF-15-15; Cook, Bloomington, USA). The guidewire was withdrawn with a rotating motion, and the process was repeated five times. After the guidewire was carefully removed and blood flow was restored, the skin incision was then closed. The sham latticement control mice underwent the same procedures without the vascular injury. SMC-Cre mice were randomly divided into control group (Sham, n = 6) and vascular injured model + TMAO group (SMC-Cre + Injured + TMAO, n = 6). SMC-PRMT5-KO mice were also used in vascular injured model + TMAO group (SMC-PRMT5-KO + Injured + TMAO, n = 6) in this study. TMAO (86 μmol) or saline was administered daily by intraperitoneal injection for 7 days [26]. The TMAO dose used in the present study was based on the dosage reported by the team discovering the relationship between TMAO and cardiovascular disease. All mice were maintained at the Animal Housing Unit of Jiangnan University (Jiangsu, China) under a controlled temperature (23–25 °C) and a 12 h light–12 h dark cycle. At least six independent mice per group from three independent experiments.

Three groups of operated animals were processed for morphological studies at 7 days after the operation, the time corresponding to peak inflammatory cell infiltration in this model [49, 50].

Cell isolation from rats and cell culture

VSMC were cultured by the explant method as described previously [51]. In brief, thoracic aortas of adult male Sprague–Dawley rats were removed and washed with cold phosphate-buffered saline (PBS). Aortic media were cut into pieces (<1 mm³) after removal of the adventitia and clamped and then maintained in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone Laboratories Inc., Logan, UT, USA) supplemented with 20% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C in humidified air with 5% CO₂. The purity of VSMC was confirmed by positive staining with alpha-smooth muscle actin (α-SMA) antibody. VSMC were used in passages 3–6.

Primary bone marrow-derived macrophages (BMDM) for adhesion assay were obtained from femoral bone marrow suspensions of C57BL/6 mice, and plated at 3 × 10⁶ cells/mL and differentiated for 7 days in the DMEM supplemented with 10% FBS containing macrophage-colony stimulating factor (M-CSF, 20 ng/mL). All cells were regularly tested negative for mycoplasma contamination.

Cell viability measurements

The 3-(4,5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium (MTT) bromide assay kit (Beyotime, Shanghai, China) was used to measure cell viability as described previously [52]. In brief, VSMC were inoculated in a 96-well microplate and treated with indicated concentrations of TMAO for 24 h or TMAO (600 μM) for the indicated periods. MTT working solution (10 μL/well) was added to the wells, and the plate was incubated at 37 °C for 4 h. Subsequently, formazan crystals were dissolved using 100 μL of formazan dissolution reagent. Viable cells were counted by absorbance measurements with a monochromator microplate reader (BIO-TEK, Winskośi, VT, USA) at a wavelength of 570 nm.

Small interfering RNA and plasmid DNA transfection

To introduce small interfering RNA (siRNA) into VSMC, the cells were plated on 6-well plates at 30–50% confluence before transfection. Transfection of cells with siRNA was performed using Lipofectamine 3000 transfection reagent (Invitrogen, CA, USA), following the manufacturer’s instructions. Two siRNA targeting Nox4 (siRNA PRMT5, NF-κB p65 siRNA, and NF-κB p65 siRNA were designed by GenePharma (Shanghai, China). The ones with the highest knockdown efficacy were selected for the following experiments. Sequences of siRNA were described in Suppl. Table S1. Gene silencing was monitored by Western blot assay after 48 h of post-transfection. Protein expression of PRMT5, NF-κB p65, Nox2, Nox4, and NF-κB in TMAO-treated VSMC was effectively attenuated by RNAi-based knockdown (>75%) (Suppl. Fig. 7).

The plasmids pcDNA3.1/Flag-p65WT, pcDNA3.1/Flag-p65R30A (replacement of arginine 30 by alanine, R30A) were purchased from GENEWIZ (Suzhou, China). For transfection, adherent VSMC of 60% confluence in 6-well plates were transfected using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions.

Western blot analysis

Western blot analysis was performed as previously described [53]. Cells were homogenized in ice-cold lysis buffer RIPA containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich, Shanghai, China). Equal amounts (30 μg) of protein were separated by electrophoresis in 10% sodium dodecyl sulfate-polyacrylamide electrophoresis gel and transferred to a polyvinylidene difluoride membrane (Millipore, MA, USA). After blocking with 5% nonfat dried milk and then incubated overnight at 4 °C with appropriately diluted primary antibodies. After being washed with Tris-buffered saline (TBS)-TWEEN 20, the membranes were incubated with horseradish peroxidase-conjugated anti-rabbit (Cat#65-6120) or anti-mouse secondary antibodies (Cat#62-6520) (Thermo Fisher, WA, USA, dilution 1:5000) for 2 h at room temperature, and immunoreactivity was analyzed by Western Lightening Plus enhanced chemiluminescence (Millipore) according to the manufacturer’s instructions. Antibodies for PRMT5 mAb (Cat#ab109451, 1:10,000) and SYM-10 (Cat# 07-412, 1:1000) were purchased from Abcam (Shanghai, China) and Millipore (CA, USA), respectively. Antibodies for Nox1 mA (Cat# A8527, 1:1000), Nox2 mA (Cat# A19701, 1:1000), and β-actin mA (Cat# AC038, 1:50,000) were purchased from Abclonal (Wuhan, China). Antibodies for Nox4 pAb (Cat# 14347-1-AP), NF-κA pAb (Cat# 12981-1-AP), VCAM-1 mA (Cat# 11444-1-AP), Flag pAb (Cat# 20543-1-AP), and NF-κB p65 pAb (Cat# 10745-1-AP, 1:1000) were purchased from Proteintech (Wuhan, China).

Immunofluorescence staining

Immunofluorescence staining was performed as described previously [54]. At 7-day post-injury periods, the carotid arteries were harvested after circulation perfusion and fixed with 4% paraformaldehyde dissolved in PBS and paraffin-embedded for immunofluorescence analyses. After antigen retrieval process (Improved citrate antigen retrieval solution, P0083, Beyotime, Shanghai, China), the arterial sections were blocked in PBS with 10% goat serum for 1 h and incubated overnight with VCA-1 antibody (Cat# A19131, Abclonal, Wuhan, China, 1:100) or CD68 (Cat# A13266, Abclonal, Wuhan, China, 1:100) at 4 °C. The sections were then washed with PBS and incubated with Alexa 555-labeled anti-mouse IgG (Cat#A21236, Invitrogen, USA, 1:200) or Alexa 647-labeled anti-mouse IgG (Cat#44145, Cell Signaling Technology, USA, 1:200) diluted in PBSB (1% BSA in PBS) for 1 h at room temperature. Cell nuclei were stained with DAPI. Immunofluorescence staining was analyzed in a blinded manner by randomly numbering the samples. The images were captured using a confocal laser scanning microscope (LSM880, Carl Zeiss) and analyzed using ImageJ software (NIH, Bethesda, MD, USA).

Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated using TRIzol reagent (Life Technologies, MA, USA) and was subjected to reverse transcription using Prime-Script RT reagent kit (TaKaRa Biotechnology, Kyoto, Japan) following the manufacturer’s instructions. SYBR® Green RT-qPCR was performed using RT-qPCR system (BIO RAD CFX Connect, CA, USA). The relative mRNA levels were normalized to β-2-microglobulin levels and fold changes for each mRNA were made on comparative cycle threshold method (2−ΔΔCt). The primers used in this study were provided in Supplementary Table S2.

Co-immunoprecipitation

Cells were lysed in RIPA lystate (weak) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail after the corresponding treatment and washed with PBS. The cell lystate was centrifuged at 12,000×g for 15 min. The supernatant was transferred to a new tube and a portion was reserved for input. Immunoprecipitation was performed by mixing cleared cell lysates with the antibodies or normal rabbit IgG as a negative control overnight at 4 °C on a rotator. Protein A/G plus magnetic beads were then added and incubated at 4 °C for 2 h. After washing three times using lysis buffer supplemented with protease inhibitor, complexes were released by boiling for 5 min in 2x loading buffer and subjected to Western blot analyses.

Cell adhesion assay

BMDM were labeled by BCECF-AM (10 μM, Beyotime Biotechnology, Shanghai, China) at 37 °C for 1 h in DMEM. The cells were then washed with culture medium and centrifuged. VSMC grown on 12-well plates were transfected with siRNA or plasmid and then stimulated with TMAO (600 μM) for 24 h. After washing twice with PBS, the labeled BMDM (2 × 10⁴)}
cells/mL were seeded onto VSMC monolayers and incubated for 1 h in a CO2 incubator. The nonadherent BMDM were removed by washing with PBS. The cell adhesion was detected using a fluorescence microscope (Zeiss Axio Vert A1, Carl Zeiss, Niedersachsen, Germany). Six images were taken in each well and the number of bound BMDM was counted per image area.

Detection of O2•− and H2O2 production in VSMC
TMAO-induced O2•− and H2O2 production were measured by DHE and Amplex Red probes, respectively [55]. Briefly, VSMC were transfected with Nox2 or Nox4 siRNA for indicated times before stimulation of TMAO. After TMAO treatment, cells were washed with PBS and incubated with DHE (10 μM) or Amplex Red (50 μM) for 30 min in the dark at 37 °C. Cells were washed with PBS for three times and the fluorescence density was measured by a Varioskan Flash Multimode Reader (Thermo Scientific, MA, USA) or a Zeiss LSM880 microscope (Zeiss, Göttingen, Germany).

Quantification of TMAO
Quantification of TMAO in plasma samples was performed using stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS, Q Exactive, Thermo Fisher Scientific; MA, USA) and monitored in positive MRM mode using characteristic precursor–product ion transitions: m/z 76 → 58. The internal standard trimethylamine-d9-N-Oxide TMAO (d9-TMAO) was added to plasma samples before protein precipitation and monitored in positive MRM mode at m/z 85 → 60 [56]. Various concentrations of TMAO standards and a fixed amount of internal standards were spiked into control plasma to prepare the calibration curves for quantification of plasma analytes.

Statistical analysis
Sample sizes were determined based on preliminary studies. Animal studies were designed to generate groups of equal size using blinded analyses. No sample was excluded from these analyses. The number of replicates and statistical method were indicated in each figure legend. Quantitative data were expressed as a mean ± standard deviation (SD). All data analyses were performed with GraphPad Prism 8 software (GraphPad, La Jolla, CA, USA). P < 0.05 was considered statistically significant. Statistical analyses of differences were performed by the Student’s t-test between two groups and one-way analysis of variance followed by Tukey’s test when comparing among multiple groups. These statistical tests were selected to be appropriate for the normality of distribution and homogeneity of variance.

DATA AVAILABILITY
The main data supporting the findings of this study are available within the article and its Supplementary Figures. Extra data are available from the corresponding author upon request.

REFERENCES
1. Ellulf MS, Patimam L, Khaza’ai H, Rahmat A, Abed Y, Ali F. Atherosclerotic cardi-ovascular disease: a review of initiators and protective factors. Inflammopharmacology. 2016;24:1–10.
2. Lim S, Park S. Role of vascular smooth muscle cell in the inflammation of atherosclerosis. BMB Rep. 2014;47:1–7.
3. Moriya J. Critical roles of inflammation in atherosclerosis. J Cardiol. 2019;73:22–27.
4. Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived trimethylamine-N-oxide aggravates angiostatin II-induced hypertension. Redox Biol. 2021;46:102115.
5. Wierda RJ, Geutskens SB, Jukema JW, Quax PH, van den Elsen PJ. Epigenetics in cardiovascular disease. 2016;351:1214–8.
6. Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–8.
7. Wierda RJ, Geutskens SB, Jukema JW, Quax PH, van den Elsen PJ. Epigenetics in cardiovascular disease. 2016;351:1214–8.
8. Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015;72:2041–59.
9. Wang N, Yan H, Wu D, Zhao Z, Chen X, Long G, et al. PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma. Cell Death Dis. 2020;11:864.
10. Webb LM, Narvaez Miranda J, Amici SA, Sengupta S, Nagy G, Guevara-de-Arellano M. NF-κB/mTOR/MYC axis drives PRMT5 protein induction after T cell activation via transcriptional and non-transcriptional mechanisms. Front Immunol. 2019;10:524.
11. Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–8.
12. Hou Z, Peng H, Ayyanath K, Yan KP, Langer EM, Longmore GD, et al. The LIM protein AUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol Cell. 2008;32:2198–207.
13. Bandyopadhyay S, Harris DP, Adams GN, Lause GE, Tillmaand EG, et al. HDAX9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules. Mol Cell Biol. 2012;32:2102–13.
14. Ma G, Pan B, Chen Y, Guo C, Zhao M, Zhang L, et al. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing mono-cyte adhesion. Biosci Rep. 2017;37:BSR20160244.
15. Kietzmann T, Petry A, Shvestova A, Gehrlich J, Goriach A. The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system. Br J Pharm. 2017;174:1533–54.
16. Lutgen E. Epigenetic quantification of VSMC in control. Arterioscler Thromb Vasc Biol. 2019;39:2199–2200.
17. Sun HJ, Zhao MX, Lyu YN, Ren XS, Chen Q, Li YH, et al. Salusin-β induces cell formation and monocyte adhesion in human vascular smooth muscle cells via miR155/NOX2/NFκB pathway. Sci Rep. 2016;6:23596.
18. Lozhkin A, Vendrov AE, Pan H, Wickline SA, Madamanchi NR, Runge MS, et al. NADPH oxidase 4 regulates vascular inflammation and aging in atherosclerosis. J Mol Cell Cardiol. 2017;102:10–21.
19. Chatterjee B, Ghosh K, Suresh L, Kanade SR, Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells. Mol Cell Biochem. 2019;455:73–90.
20. Koay YC, Chen Y-C, Wali JA, Luk AWS, Li M, Doma H, et al. Plasma levels of trimethylamine-N-oxide can be increased with ‘healthy’ and ‘unhealthy’ diets and do not correlate with the extent of atherosclerosis but with plaque instability. Cardiovasc Res. 2020;117:435–49.
21. Fu BC, Bullar MAJ, Randolph TW, Franke AA, Monroe KR, Cheng I, et al. Asso-ciations of plasma trimethylamine N-oxide, cholrine, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fucal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am J Clin Nutr. 2020;111:1226–34.
22. Hampton T. Ongoing research points to key role of gut microbes in cardiovas-cular health. Circulation. 2016;134:1687–8.
23. Tang WWH, Hazen SL. Microbiome, trimethylamine N-oxide, and cardiometabo-litic disease. Transl Res. 2017;179:108–15.
24. Koeth RA, Wang Z, Levison BS, Bufla JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–85.
25. Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary athero-sclerosis burden. J Am Soc Nephrol. 2016;27:305–13.
26. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5:e002767.
27. Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3–SOD2–mTRoS signaling pathway. J Am Heart Assoc. 2017;6:e006347.
28. Blanc RS, Richard S. Arginine methylation: the coming of age. Mol cell. 2017;65:24–28.
29. Xu J, Xu X, Wang B, Ma Y, Zhang L, Xu HU, et al. Nuclear carbonic anhydrase 68 associates with PRMT5 to epigenetically promote IL-12 expression in innate response. Proc Natl Acad Sci USA. 2017;114:8620–5.
30. Jefferis K, Jassum ST, Cho EC, Sheehan S, Edelmann M, Kessler B, et al. Arginine methyl transferase regulates the p53 response. Nat Cell Biol. 2008;10:1431–9.
31. Wei H, Wang B, Miyage M, She Y, Gopalan B, Huang DB, et al. PRMT5 dimethylates the p56 subunit to activate NF-κB. Proc Natl Acad Sci USA. 2013;110:13516–21.
32. Wang L, Qiu XM, Hao Q, Li DJ. Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptor β mediating nitrite oxide production and NF-κB suppression in endothelial cells. Cell Death Dis. 2013;4:e551.
33. Qin M, Luo Y, Li S, Sun J, Yang K, Sun G, et al. Ginsenoside F1 ameliorates endothelial cell inflammation injury and prevents atherosclerosis in mice through A20-mediated suppression of NF-κB signaling. Front Pharm. 2017;8:953.
34. Zerfaoui M, Suzuki Y, Naura AS, Hans CP, Nichols C, Boulares AH. Nuclear translocation of p65 NF-κB-pa8 is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction. Cell Signal. 2008;20:186–94.
35. Majdalawieh A, Ro HS. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediat Inflamm. 2010;2010:823821.

36. Huang B, Yang XD, Lamb A, Chen LF. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal. 2010;22:1282–90.

37. Ockinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-xB signaling pathways. Nat Immunol. 2011;12:695.

38. Yan S, Zhang X, Zheng H, Hu D, Zhang Y, Guan Q, et al. Clomatin expression inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB K kinase/NF-kappa B pathway. Free Radic Biol Med. 2015;78:190–201.

39. Zhang T, Park KA, Li Y, Byun HS, Jeon J, Lee Y, et al. PHF20 regulates NF-xB signaling by disrupting recruitment of PP2A to p65. Nat Commun. 2013;4:2062.

40. Harris DP, Bandypadhyay S, Maxwell TJ, Willard B, DiCorleto PE. Tumor necrosis factor (TNF)–a induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)–mediated nuclear factor (NF)–xB p65 methylation. J Biol Chem. 2014;289:15328–39.

41. Angelini F, Pagano F, Bordin A, Milan M, Chimenti I, Peruzzi M, et al. The impact of environmental factors in influencing epigenetics related to oxidative states in the cardiovascular system. Oxid Med Cell Longev. 2017;2017:2712751.

42. Zampetaki A, Dudek K, Mayr M. Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodelling. Free Radic Biol Med. 2013;64:69–77.

43. Katooj AA, Pothenimi NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 2017;19:42.

44. Jagadeesha DK, Takapo M, Banfi B, Bhalla RC, Miller FJ Jr. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res. 2012;93:406–13.

45. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol. 2009;29:480–7.

46. Datla SR, McGrail DJ, Vukelic S, Huff LP, Lyle AN, Pounkova L, et al. Poldip2 controls vascular smooth muscle cell migration by regulating focal adhesion turnover and force polarization. Am J Physiol Heart Circ Physiol. 2014;307: H945–957.

47. Burtenshaw D, Hakimjavadi R, Redmond EM, Cahill PA. Nox, reactive oxygen species and regulation of vascular cell fate. Antioxidants. 2017;6:90.

48. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res. 2009;105:249–59.

49. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000;20:335–42.

50. Croce K, Gao H, Wang Y, Mookta R, Sakuma M, Shi C, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120:427–36.

51. Liu YH, Zhang QY, Pan LL, Liu SY, Xu P, Luo XL, et al. NADPH oxidase 4 contributes to connective tissue growth factor expression through Smad3-dependent signaling pathway. Free Radic Biol Med. 2016;96:174–84.

52. Dong X, Wu D, Zhang Y, Jia L, Pan X, Sun J, et al. Cathelicidin modulates vascular smooth muscle cell phenotypic switching through ROS/IL-6 pathway. Antioxidants. 2020;9:491.

53. Pan LL, Liang W, Ren Z, Li C, Chen Y, Niu W, et al. Cathelicidin-related antimicrobial peptide protects against ischaemia reperfusion-induced acute kidney injury in mice. Br J Pharmac. 2020;177:2726–22.

54. Bai Y, Pan LL, Zhou Q, Zhao C, Xie Y, Wu C, et al. Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury. BMC Med. 2019;17:42.

55. Yan S, Zhang X, Zheng H, Hu D, Zhang Y, Guan Q, et al. Clomatin expression inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-xB pathway. Free Radic Biol Med. 2015;78:190–201.

56. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.

AUTHOR CONTRIBUTIONS
HL and L-LP performed experiments and analyzed data. KJ assisted the experiments. ZR critically reviewed the manuscript. L-LP and JS designed and interpreted experiments. L-LP, JS, and HL wrote the paper.

FUNDING
The work was supported by funds from the National Natural Science Foundation of China (Grant No: 81973322). The Recruitment Plan for High-level, Jiangsu Province Recruitment Plan for High-level, Innovative and Entrepreneurial Talents (Innovative Research Team) of Jiangsu Province, the Fundamental Research Funds for the Central Universities (Grant Nos: JUSRP210137 and JUSRP22007), Jiangsu Province Qing Lan Project and Jiangsu Province “Six Summit Talents” Program (Grant No: YY-038), Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Wuxi Taihu Talent Project and Postgraduate Research and Practice Innovation Program of Jiangsu Province (Grant No: KYXQ20-1862).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Animal Ethics Committee of Jiangnan University (JNU.20180615C1440210).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04719-7.

Correspondence and requests for materials should be addressed to Jia Sun or Li-Long Pan.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

H. Liu et al.